Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

venetoclax 158Cytarabine 118Cyclophosphamide 111Specimen Handling 104Azacitidine 104fludarabine 91Biopsy 79Rituximab 50Methotrexate 45Daunorubicin 45fludarabine phosphate 42Vincristine 38Dexamethasone 37Magnetic Resonance Spectroscopy 36Injections 35Decitabine 35Granulocyte Colony-Stimulating Factor 32blinatumomab 31Mycophenolic Acid 30Idarubicin 30Whole-Body Irradiation 29Prednisone 28ibrutinib 27Tacrolimus 27Etoposide 27Doxorubicin 27Busulfan 27acalabrutinib 24Melphalan 24Filgrastim 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Succimer × Other hematologic neoplasm × 90 days × Clear all
NCT06811233 2026-04-23

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

M.D. Anderson Cancer Center

Phase 2 Recruiting
140 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡